CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd. develops regenerative medicine products based on its recombinant human collagen technology platform. The company is focused on bioinks and scaffold materials used in 3D bioprinting, as well as tissue-related products for orthopedic, prosthetic, and surgical applications, with operations run from Israel and access to U.S. capital markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRecombinant collagen-based inks used as the base material for bioprinting tissue constructs.
Collagen-derived scaffold materials designed to support tissue regeneration and implant applications.
Development programs that advance collagen-based platforms and related applications.
Products and materials for orthopedic, prosthetic, and surgical uses.
Products
Reported · share of revenue- Revenues From Milestones84.4 %
- Revenues From Sales of Goods15.6 %
Source: 20-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
CollPlant sells into life sciences and regenerative medicine markets, where customers need advanced biomaterials for research, development, and clinical translation. Its buyers are typically biotechnology and medical-device partners, research organizations, and commercial collaborators that use collagen-based materials in bioprinting or tissue engineering workflows. End users are often hospitals, surgeons, and patients indirectly, through partner products or clinical programs.
They buy collagen-based materials and platform access to develop regenerative and bioprinted products.
They use bioinks and scaffold materials for preclinical and translational research.
They incorporate biomaterials into orthopedic, prosthetic, or surgical applications.
Strategy
CollPlant’s strategy centers on its recombinant human collagen platform and the expansion of its 3D bioprinting and regenerative medicine offerings. Recent disclosures point to product innovation around ready-to-print bioinks and continued development of its collagen-based portfolio, which supports differentiation with partners that need scalable, human-collagen materials. Protecting the platform’s technical position and advancing commercial collaborations are central to its long-term value creation.
A broader product set increases use cases and partner adoption in bioprinting and regenerative medicine.
Partners provide validation, distribution reach, and downstream commercialization pathways.
Technical differentiation around recombinant human collagen supports pricing power and customer retention.
Geography
2025CollPlant is headquartered in Israel and serves a business model that is global in research, partnering, and commercialization. The company also accesses U.S. capital markets as a foreign private issuer, while its products and collaborations are relevant to customers across North America, Europe, and other international life-science markets. Geography matters because regulatory pathways, clinical adoption, and partner networks differ materially by region.
Share of the revenue the company reports by geography.
Risks
CollPlant faces development, commercialization, and financing risks typical of early-stage biomaterials and medical technology companies. Its products depend on adoption by partners and customers, regulatory acceptance, and successful execution of product launches, while foreign issuer listing requirements and equity market conditions can also affect the business. Because revenue is tied to emerging applications, delays in partner programs or product adoption can have outsized effects.
- Commercialization and adoption riskImpact: HighLikelihood: High
Bioinks and biomaterials must be adopted by partners and end users before they can scale meaningfully.
Exposure: 3D bioprinting and regenerative medicine products
- Regulatory and clinical riskImpact: HighLikelihood: Medium
Medical and tissue-related products require regulatory clearance and successful clinical or preclinical progress.
Exposure - Technology and execution riskImpact: HighLikelihood: Medium
Platform companies must keep improving materials performance and manufacturing reproducibility.
Exposure: rhCollagen and bioink development
- Capital market and listing compliance riskImpact: MediumLikelihood: Medium
The company depends on public-market access and must satisfy exchange requirements.
Exposure: Nasdaq listing status
Accounting
Judgemental itemsDevelopment-stage activities are expensed as incurred, shaping reported losses and comparability.
Impact: Material to operating results
Equity awards can be a meaningful non-cash expense for small biotech companies.
Impact: Affects operating loss and EPS
Israeli operations reporting in U.S. dollars can create translation volatility.
Impact: Affects cash, expenses, and equity
Operating leases create right-of-use assets and liabilities that affect the balance sheet.
Impact: Affects leverage and asset base
Similar listed companies
Publicly listed companies with a comparable business focus.
Purple Biotech Ltd
PPBT · Pharmaceutical Preparations
Celularity Inc
CELU · Pharmaceutical Preparations
Integra LifeSciences Holdings Corporation
IART · Surgical & Medical Instruments & Apparatus
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Harvard Apparatus Regenerative Technology, Inc.
HRGN · Surgical & Medical Instruments & Apparatus
Last updated: 28/09/2026